首页 › 基金 › FARALLON CAPITAL MANAGEMENT, L.L.C. › MAZE
FARALLON CAPITAL MANAGEMENT, L.L.C. 对 MAZE 的持仓历史
MAZE THERAPEUTICS INC · 医疗保健
FARALLON CAPITAL MANAGEMENT, L.L.C. 在 Q3 2026 的 13F 申报中披露持有 MAZE(MAZE THERAPEUTICS INC)1,107,814 股,市值约 US$30.1M,约占其申报组合的 0.13%,在其申报持仓中市值排名第 46 位。 FARALLON CAPITAL MANAGEMENT, L.L.C. 最近 3 个申报季度中有 3 个季度披露了 MAZE 持仓,最早可追溯至 Q1 2026。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
FARALLON CAPITAL MANAGEMENT, L.L.C. 对 MAZE 的持仓演变
FARALLON CAPITAL MANAGEMENT, L.L.C. 于 Q1 2026 首次披露 MAZE 持仓:373,000 股(约 US$11.1M)。 该持仓在 Q2 2026 达到峰值 1,107,814 股,市值约 US$33.1M。 在 3 次申报中,FARALLON CAPITAL MANAGEMENT, L.L.C. 1 次增持、0 次减持、1 次保持不变。 最近一期申报(Q3 2026)显示持股 1,107,814 股、市值约 US$30.1M。 持仓曾出现大幅变动:Q2 2026 增持约 197% (随后一个季度股价下跌 9%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2026 | 373.00K | $11.13M | 新进 |
| Q2 2026 | 1.11M | $33.06M | 增持 |
| Q3 2026 | 1.11M | $30.11M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 MAZE 与 13F 数据
MAZE(MAZE THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 61 只申报持有 MAZE,申报仓位最大的包括:Frazier Life Sciences Management, L.P. (US$150.2M), TRV GP IV, LLC (US$133.5M), ARCH Venture Management, LLC (US$123.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 MAZE 的基金
- Frazier Life Sciences Management, L.P. 5.03M 股 · $150.18M · Q2 2026
- TRV GP IV, LLC 4.47M 股 · $133.50M · Q2 2026
- ARCH Venture Management, LLC 4.12M 股 · $122.98M · Q2 2026
- Deep Track Capital, LP 4.08M 股 · $111.00M · Q3 2026
- a16z Capital Management, L.L.C. 1.70M 股 · $50.79M · Q2 2026
- Venrock Adviser, LLC 1.60M 股 · $47.80M · Q2 2026
- Alphabet Inc. 1.39M 股 · $37.74M · Q3 2026
- BRAIDWELL LP 1.14M 股 · $34.02M · Q2 2026
- 法拉龙资本管理 1.11M 股 · $33.06M · Q2 2026
- General Catalyst Group Management, LLC 1.04M 股 · $30.91M · Q2 2026
- TRV GP V, LLC 950.80K 股 · $28.37M · Q2 2026
- Logos Global Management LP 935.00K 股 · $25.41M · Q3 2026
更多关于 FARALLON CAPITAL MANAGEMENT, L.L.C.
常见问题
How long has FARALLON CAPITAL MANAGEMENT, L.L.C. held MAZE?
FARALLON CAPITAL MANAGEMENT, L.L.C. has disclosed MAZE holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is FARALLON CAPITAL MANAGEMENT, L.L.C.'s current position in MAZE?
As of Q3 2026, FARALLON CAPITAL MANAGEMENT, L.L.C. holds 1.11M shares of MAZE (MAZE THERAPEUTICS INC), valued at $30.11M, representing 0.13% of its reported portfolio and ranking #46.
Has FARALLON CAPITAL MANAGEMENT, L.L.C. been buying or selling MAZE?
In the latest 13F filing (Q3 2026), FARALLON CAPITAL MANAGEMENT, L.L.C. held unchanged its position in MAZE. The position peaked in Q2 2026 at 1.11M shares.
Which other funds hold MAZE?
Other major institutional holders of MAZE include Frazier Life Sciences Management, L.P., TRV GP IV, LLC, ARCH Venture Management, LLC, among 61 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.